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Background: Local control rates are poor in the treatment of pancreatic cancer. We investigated the role of
hypofractionated stereotactic body radiation therapy (SBRT) for salvage or boost treatment after conventional doses
of external beam radiation therapy.
Methods: All patients treated with SBRT for pancreatic adenocarcinoma at Georgetown University from June 2002
through July 2007 were examined. Eligible patients had prior external beam radiation therapy to the pancreas.
Treatment parameters and clinical and radiographic follow-up were evaluated.
Results: Twenty-eight patients were identified who received SBRT after a median prior external beam radiotherapy
dose of 50.4 Gy. The median patient age was 63 years old and the median follow-up was 5.9 months. Twelve of
fourteen (85.7%) evaluable patients were free from local progression, with three partial responses and nine patients
with stable disease. Toxicity consisted of one case of acute Grade II nausea/vomiting, and two cases of Grade III late
GI toxicity. The median overall survival was 5.9 months, with 18% survival and 70% freedom from local progression
at one year.
Conclusions: Hypofractionated SBRT reirradiation of localized pancreatic cancer is a well-tolerated treatment. Most
patients are free from local progression, albeit with limited follow-up, but overall survival remains poor.
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Poor local control and frequent distant failure are prob-
lematic aspects of the management of pancreatic cancer.
Although conventional radiation techniques may be
employed for local control, they incur toxicity and inter-
rupt use of full dose gemcitabine, the most active sys-
temic agent for the disease. Radiation doses are limited
by the presence of critical normal structures, which in-
clude spinal cord, small bowel, stomach and kidneys.
The emerging technology of stereotactic body radiation
therapy (SBRT), as an adjunct or alternative to conven-
tional radiation techniques, offers the potential for radi-
ation dose escalation, retreatment, and/or decreased
interruption of systemic therapy. The safety, efficacy and* Correspondence: clominska@kumc.edu
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reproduction in any medium, provided the ortechnical aspects of this treatment modality have not
been fully defined.
In the absence of surgical resection, cancer of the pan-
creas is considered a uniformly lethal disease. After sur-
gery local recurrence rates are estimated to range from
50-75% [1,2]. Chemotherapy is recommended for
patients able to tolerate treatment, but response rates
for gross disease are poor. The role of radiotherapy is
controversial in both the adjuvant (post-operative) and
definitive (unresectable localized disease) settings. Sup-
porters of adjuvant radiotherapy point to the landmark
Gastrointestinal Tumor Study Group (GITSG) study,
where a survival benefit was demonstrated with the
addition of adjuvant chemoradiation and maintenance
chemotherapy versus surgery alone [3]. Detractors of ad-
juvant radiotherapy counter with the apparent detrimen-
tal effect of chemoradiation from the European Study
Group for Pancreatic Cancer (ESPAC-1) [4]. Theral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Summary of patient characteristics
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Treatment of Cancer (EORTC) trial has been interpreted
as both undermining the role of adjuvant radiation ther-
apy [5] and supporting it [6].
Recently interest has developed in the use of stereotac-
tic body radiation therapy (SBRT), which involves the
delivery of 1–5 fractions with a high dose per fraction
delivered with image guidance [7]. The conformity and
rapid dose fall-off associated with SBRT offer the poten-
tial for dose escalation [8]. SBRT also offers the potential
for retreatment of previously irradiated pancreas cancer.
This study examines the use of SBRT for reirradiation of
locally recurrent/progressive pancreatic cancer.Male 20 (71)
Female 8 (29)
Treatment intent
Boost (Initial diagnosis) 11 (36)
Salvage (Local recurrence/progression) 17 (61)




Chemoradiation only 20 (71)
Surgery + chemoradiation 8 ( 29)Materials and methods
Patients & eligibility
This is a retrospective study of all patients who received
prior external beam radiation therapy and were treated
with SBRT at Georgetown University Hospital from June
2002 to July 2007. Approval to review records was
obtained from the Georgetown University Hospital insti-
tutional review board. Eligible patients had histological
demonstration of adenocarcinoma of the pancreas with
unresectable locally recurrent or progressive disease, as
demonstrated by biopsy or imaging, and no distant me-
tastases. Disease recurrence or progression had to be
limited to the primary tumor or regional nodes within
the prior radiation field. Patients with invasion of the
duodenum or stomach were not eligible for treatment.
Twenty-eight eligible patients were identified, 11 of
whom were treated with a hypofractionated boost with
SBRT delivered within 2 months of completing external
beam radiation therapy. The remaining 17 patients
underwent salvage SBRT after imaging demonstrated
local recurrence/progression. Patient characteristics are
summarized in Table 1.Treatment planning & delivery
SBRT was delivered via the CyberKnife, an image-guided
frameless stereotactic robotic radiosurgery system
(Accuray Corporation, Sunnyvale CA) consisting of a lin-
ear accelerator mounted on a robot arm with 6 degrees of
freedom [9]. In this system, the confluence of a large num-
ber of non-isocentric pencil beams permits the treatment
of irregularly shaped target volumes with rapid dose falloff.
Twenty-three of the 28 patients had fiducials implanted
using endoscopic ultrasound (21 patients), as described
previously [10], or CT guidance (2 patients). For these
patients respiratory motion was accounted for using fidu-
cial tracking via the SynchronyTM system (Accuray Cor-
poration, Sunnyvale CA). For the remaining five patients,
the tumor recurrence was felt to have limited respiration-
related motion (e.g., retroperitoneal recurrence). In thesecases, spinal tracking was used without compensation for
respiratory motion.
Treatment planning began with acquisition of a CT with
IV and PO contrast (23/28 patients) approximately 7 days
after fiducial implantation. Scan were acquired with free
breathing with no abdominal compression or 4D CT tech-
niques used. Gross tumor volume (GTV) was delineated as
the radiographically evident gross disease by contrast CT or
PET/CT. In select cases (5/28 patients), the GTVs were
manually contoured on PET/CT, which was obtained in the
treatment position, and fused with the treatment planning
CT images. At the discretion of the treating physician, a
clinical target volume encompassing areas of potential sub-
clinical disease spread was also designated. In most cases
the CTV was the GTV. The expansion from CTV to plan-
ning target volume (PTV) was 0–5 mm. As appropriate,
organs at risk were contoured including stomach, duode-
num, kidney, and spinal cord. Primary organs at risk were
the duodenum and/or stomach. These were restricted to a
max point dose less than or equal to the prescription dose.
Kidney and spinal cord were also evaluated but the gastro-
intestinal structures were the primary planning objective.
Treatment dosimetry parameters were calculated using the
formula: conformity index=prescription isodose volume /
target volume and homogeneity index=maximum dose /
prescription dose [11]. SBRT treatment characteristics are
listed in Table 2. A variety of fractionated treatment
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patient); 27.5 Gy in 5 fractions (2 patients); 25 Gy in 5 frac-
tions (1 patient); 24 Gy in 3 fractions (10 patients); 22.5 Gy
in 3 fractions (3 patients); 21 Gy in 3 fractions (9 patients);
20 Gy in 5 fractions (2 patients).
All patients had previously undergone chemotherapy
either with 5-fluorouracil (5-FU) based therapy, gemcita-
bine, or both. Prior chemotherapy agents also included
targeted agents, platinum compounds and taxanes. Two
of the patients had concurrent capecitabine with SBRT;
no patients had gemcitabine within two weeks before or
after SBRT. Patients were treated on consecutive week-
days in most cases, and treatment was completed within
two weeks.
Follow-up & statistical analysis
Follow-up information was obtained from chart review
of imaging studies, survival information from clinical
follow-up and the social security death index. Toxicity
was graded according to the Common Terminology Cri-
teria for Adverse events, version 3.0. Survival was calcu-
lated from the date of beginning SBRT. Local control
was evaluated by CT or PET/CT. Patients were classified
as free from local progression if the radiologist reported
stable or decreased tumor size or FDG-activity; local fail-
ures were denoted if the radiologist reported tumor pro-
gression by increase in tumor size or FDG-activity. For
CT scans, RECIST criteria were used. For PET scans, re-
sponse was classified subjectively based on the impres-
son of the radiologist. Due to the extent of prior
treatment and the difficulty of distinguishing inflamma-
tory changes from residual tumor, no patients were clas-
sified as complete responses. Kaplan-Meier analysis was
used for estimates of local control and overall survival.
Results
Clinical follow-up was available for all patients and radio-
logical follow-up was available for 14 patients (Figure 1).
The median duration for any follow-up was 5.9 monthsTable 2 Treatment characteristics
Treatment Parameter Median (range)
Total SBRT dose (Gy) 22.5 (20–30)
SBRT dose per fraction (Gy) 7 (4–8)
Number of fractions 3 (3–5)
Isodose line 75% (60-90%)
Max point dose to stomach (Gy) 20 (10–30)
Max point dose to small bowel (Gy) 20 (13–30)
Homogeneity index 1.3
Conformity index 1.6
Target volume (mL) 44 (16–198)
Volume receiving prescription dose (mL) 69 (22–223)(range, 1–27 months), and the median radiographic
follow-up was 3.5 months (range, 1–16 months). Free-
dom from local progression was obtained in 12/14
patients (86%). At last radiological follow-up, 6 (43%)
patients were free from local progression and distant
progression, 6 (43%) patients were free from local pro-
gression but experienced distant failure, and 2 (14%)
patients had both local and distant progression by CT
scan. Of the 6 patients with local control, 3 (50%) were
partial responders (two by PET and one by CT) and the
remainder (50%) were locally stable. For the two patients
with PET/CT scans, FDG avidity resolved but there was
a residual mass on CT, and they were considered to have
a partial response. The response rate for all patients with
radiographic follow-up was 21%.
At the time of last follow-up in June 2008, all patients
had died. Overall survival is shown in Figure 2. Median
overall survival was 5.9 months from the date of SBRT
treatment, ranging from 1–27 months. Eleven patients
(39%) had 9 months or greater survival. Survival at one
year was 18%.
Treatment was well tolerated; acute toxicity consisted of
Grade I fatigue and nausea, with the exception of one pa-
tient who required IV hydration for Grade II nausea and
vomiting while on treatment, but completed treatment
without delay. There were two late Grade III GI complica-
tions. In one case a patient suffered a bowel obstruction
which resolved with conservative management. The sec-
ond patient had a gastric perforation which resolved with
conservative management. Both patients were treated with
21 Gy in three fractions, and had received 50.4 Gy to the
abdomen previously. For the patient with a gastric perfor-
ation, the maximum point dose to the stomach was 10 Gy;
the maximum point dose to the small bowel was 16 Gy in
the patient with a bowel obstruction. Given the mobility
of these organs at risk between or even during treatments,Figure 1 Actuarial plot of freedom from local progression from
date of stereotactic body radiotherapy.
Figure 2 Actuarial plot of survival from date of stereotactic
body radiotherapy.
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is inevitable. Qualitiative review of the plans did not reveal
a difference in dose to or volume of the critical structures
in patients with or without complications. It is now the
practice of the authors to use five fractions, which poten-
tially lowers the dose received by a mobile organ at risk.Discussion
The current study examines the use of fractionated
SBRT for treatment of pancreatic adenocarcinoma in the
setting of prior conventionally fractionated external
radiotherapy. Our interest in the use of SBRT for reirra-
diation of pancreas cancer arises from the difficulty of
obtaining local control in this disease. Even in the setting
of modern multi-modality therapy (surgery and
gemcitabine-based chemotherapy or chemoradiation)
local recurrence remains frequent [12,13]. The RTOG
97–04 trial demonstrated local recurrence rates of 23%
(gemcitabine arm) to 28% (5-FU arm) with the adminis-
tration of 50.4 Gy adjuvant chemoradiation [13]. In
patients with unresectable local disease, response rates
to either chemoradiation or chemotherapy are poor. For
example, in a recent publication from the Eastern Co-
operative Oncology Group (ECOG) reporting gemcita-
bine plus radiotherapy versus gemcitabine alone, the
response rate was 5% for chemotherapy alone and 6%
for chemoradiation, although rates of stable disease were
higher with the addition of radiation (35% vs 68%) [14].
The potential benefits of SBRT include decreased treat-
ment time, dose intensification to gross disease, and
minimal interruption of systemic therapy [15]. These
must be weighed against the disadvantages, which in-
clude the potential for increased toxicity, principally
gastrointestinal, the prevalence of distant failure negat-
ing any theoretical survival advantage for local control,
and the difficulty in demonstrating long-term localcontrol or palliative benefit given the overall poor prog-
nosis of these patients.
Investigation of SBRT for pancreas cancer has
included a series of studies from Stanford [8,15-17]. A
Phase I dose escalation study demonstrated the toler-
ability of 25 Gy delivered in a single fraction, producing
100% local control in all 6 patients treated, with a me-
dian follow-up of 4.5 months [16]. The prevalence of
distant failure negated any survival benefit and demon-
strated the ongoing importance of systemic therapy in
this disease. A phase II trial investigated the use of 5-
FU based chemoradiation with 45 Gy delivered via in-
tensity modulated radiation therapy to the tumor and
regional lymph nodes, followed by a 25 Gy SBRT boost
[8]. Nineteen patients were enrolled, of whom sixteen
underwent SBRT. Two patients experienced Grade III
GI toxicity (gastroparesis), and additional patients devel-
oped duodenal ulcers. Although local control was favor-
able at 94%, distant progression remained problematic,
and in conjunction with the increase seen in side
effects, prompted discarding of the protocol. Systemic
therapy was intensified in the subsequent Phase II trial
which incorporated a single fraction 25 Gy SBRT treat-
ment into a regimen of gemcitabine chemotherapy [17].
Sixteen patients were treated with full-dose gemcitabine,
with SBRT performed between cycles one and two, fol-
lowed by more chemotherapy until progression or toler-
ance was reached. Only three patients failed locally, but
distant progression remained frequent (15/16 patients)
and overall survival was 11 months. Late gastrointes-
tinal toxicity remained problematic with five patients
experiencing Grade II, and two patients Grade III/IV
toxicity. The Stanford studies [8,16,17] demonstrate po-
tentially encouraging rates of local control when taken
together, but the prevalence of distant progression
prompted additional chemotherapy and external beam
radiotherapy, with a concerning concomitant increase in
toxicity. The durability of local control is difficult to
characterize given poor overall survival. The Stanford
experience has been recently summarized in a publica-
tion of 77 patients, with freedom from local progression
rates of 84% at 1-year, and a 1-year overall survival rate
of 21% [15].
Other reports of SBRT for pancreatic cancer include a
phase II trial of 22 patients from Denmark that showed
concerning levels of acute (79% Grade II or greater) and
late (22% severe, not further defined by authors) GI tox-
icity with a poor local control rate of 57% [18]. A caveat
to these results is that an abdominal compression system
was used for treatment delivery, and the prescription
was 45 Gy in three fractions to the clinical target vol-
ume, which included the tumor and surrounding edema.
An expansion of 0.5 to 1 cm created a planning target
volume with an average size of 136 mL which was
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A series of 36 patients who underwent SBRT for locally
advanced pancreatic cancer has recently been reported
from Beth Israel [19]. Patients with unresectable, non-
metastatic disease underwent 3 fractions of SBRT fol-
lowed by gemcitabine chemotherapy. Dose to the small
bowel was limited to less than 10 Gy per fraction; the
prescribed tumor dose varied (24 Gy in 3 fractions,
30 Gy in 3 fractions, or 36 Gy in 3 fractions) depending
on the separation between the tumor and duodenum.
The local control rate was 78% with a median overall
survival time of 14.3 months. Toxicities included 9 acute
Grade II, 3 acute Grade III events, and 2 late Grade III
events attributed to SBRT. The University of Pittsburgh
has reported a series of 71 patients who underwent
SBRT for locally advanced adenocarcinoma of the pan-
creas for indications including locally unresectable dis-
ease (40 patients), local recurrence (11 patients),
metastatic disease (8 patients) and positive margins after
resection (12 patients) [20]. Sixty-seven patients were
treated with a single fraction of 18–25 Gy and the re-
mainder received fractionated treatment. Freedom from
local progression was 65% overall and 49% at one year
with a median overall survival of 10 months. Grade I-II
GI toxicity was found in 40% of patients but higher
grade toxicity was minimal, consisting of 3 patients with
acute Grade III GI toxicity. The planning volume was
gross disease with a 2 mm margin, and the median
tumor volume was 17 mL.
Descriptions of SBRT in the treatment of previously
irradiated pancreas cancer are scarce in the literature.
There are 16 cases described in the Stanford boost trial
[8]. Fifteen patients in the Pittsburgh series had received
prior radiotherapy to a median dose of 45 Gy [20]. How-
ever, the Pittsburgh study did not report outcomes sep-
arately for the patients with prior radiation, limiting the
conclusions that can be drawn about the use of SBRT in
the setting of prior radiation. Seo et al retrospectively
reported the largest series after external beam radiother-
apy (40 Gy in 20 fractions) as a planned boost [21]. 15–
17 Gy was delivered as a single fraction. One year local
progression free survival was 70% with 25 patients evalu-
able. One Grade IV late bowel obstruction was seen.
Reirradiation is a clinically relevant subject of investi-
gation given that approximately one-fourth of all
patients who undergo optimal trimodality therapy suffer
from local failure. For patients with residual or recurrent
localized disease after definitive treatment, current treat-
ment options are limited. Response rates are poor with
chemotherapy alone and surgical resection is possible in
only highly selected cases. Though patients also have
significant risk for development of regional or distant
disease, local progression may cause significant morbid-
ity. SBRT has been shown to provide excellent localcontrol rates when used in the definitive setting. The
minimal toxicity and short treatment duration of SBRT
allow for the early resumption of systemic chemother-
apy. Our finding of 70% freedom from local progression
at one year is similar to the Stanford series (84% at one
year) [15] and more encouraging then the Danish results
[18]. However, interpretation of local control is limited
by the patients lost to radiographic follow-up, the diffi-
culty of interpreting CT findings, and short follow-up
secondary to distant progression and patient mortality.
Additional information may be gained by increasing use
of PET/CT [22]. Anecdotally, the current series includes
two patients who had prolonged PET responses (nine
months to a year) after salvage SBRT despite residual
CT masses, who remained free of local disease progres-
sion without additional therapy. Both ultimately failed in
the peritoneum.
Interpretation of our results includes consideration of
the limitations inherent to a retrospective review. These
include selection bias, patient heterogeneity, the use of
SBRT as either boost or salvage, the use of a variety of
fractionation schemes, and exposure to a range of che-
motherapies. Additionally, our radiographic follow-up is
limited, making interpretation of freedom from local
progression difficult. Distant failure remains problematic
and survival poor. More detailed evaluation of palliative
response, including quality of life measures, would be in-
formative in future studies. Given the poor prognosis for
these patients and the limited responses to the available
treatment options, we feel our series provides valuable
information about an acceptable level of toxicity for add-
itional local treatment in these heavily previously treated
patients.
A disparity exists in the reported toxicities for SBRT.
The Pittsburgh [20], Beth Israel [19], and Stanford single
SBRT alone and boost trials [8,16] suggest Grade III and
higher toxicities are less than 10-15% with SBRT. The
Danish study [18] and Stanford SBRT with gemcitabine
study [17] suggest significantly higher rates of toxicity.
The current series suggests that with modest hypofrac-
tionation of SBRT (3–5 fractions) to limited volumes,
treatment can be delivered with acceptable acute and
late GI toxicity (less than 10%) in the setting of prior
chemotherapy and definitive doses of external beam
radiotherapy. The short follow-up limits interpretation
of late toxicity. We report detailed evaluation of treat-
ment plans, including treated volumes, conformity and
homogeneity indices, and doses to critical structures that
should prove useful to other investigators wishing to
evaluate SBRT programs for pancreas cancer. The
authors favor fractionation with SBRT in pancreas can-
cer given that increasing dose per fraction is associated
with increased late effects. Because the small bowel is a
mobile structure mounted on the mesentery it has the
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tween fractions; in effect, feathering the dose to any
given portion of bowel.
Conclusion
Our findings demonstrate acceptable toxicity and poten-
tially encouraging freedom from local progression with
fractionated SBRT for pancreas cancer in the setting of
prior chemotherapy and radiotherapy. Given the high
rates of distant progression, improvements in systemic
therapy remain desirable. SBRT can be interdigitated
with minimal interruption in full dose systemic therapy.
Future investigation might include the use of novel sys-
temic agents or radiosensitizers, rigorous quality of life
assessment of palliative benefit, and incorporation of
metabolic tumor information. It is our practice to ob-
serve selected patients with local recurrence for a period
of time while on systemic therapy, and in the absence of
evidence of systemic failure, to offer SBRT after 3–
6 months of localized disease with the goal of improving
local control, while minimizing local overtreatment of
patients with occult metastatic disease.
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